Neonatal Guillain-Barre syndrome: Blocking antibodies transmitted from mother to child

Neurology

Volumn 53, Issue 6, 1999, Pages 1246-1253

  Buchwald, Brigitte ^a,b   De Baets, Marc ^a   Luijckx, Gert Jan ^c   Toyka, Klaus V ^c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Neurologische Klinik   (Germany)

^c NONE

Author keywords

Autoantibodies; GBS; Neuromuscular junction; Patch clamp

Indexed keywords

BLOCKING ANTIBODY; IMMUNOGLOBULIN G;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CASE REPORT; CLINICAL FEATURE; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; MOTOR NERVE CONDUCTION; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PATCH CLAMP; PLACENTAL TRANSFER; PRIORITY JOURNAL; RAT;

EID: 0032834345     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.6.1246     Document Type: Article

References (41)

1. Hartung HP, Toyka KV, Griffin JW. Guillain-Barré syndrome and chronic demyelinating inflammatory polyradiculoneuropathy. In: Antel J, Birnbaum G, Hartung HP, eds. Clinical neuroimmunology. Oxford: Blackwell Science, 1998:294-306.
2. Luijckx GJ, Vies J, de Baets M, Buchwald B, Troost J. Guillain-Barré syndrome in mother and newborn child. Lancet 1997;349:27.
3. Keesey J, Lindstrom JM, Cokeley H, Herrmann C. Antiacetylcholine receptor antibody in neonatal myasthenia gravis. N Engl J Med 1977;296:55. Letter.
4. Oosterhuis HJGH. Myasthenia gravis. Groningen Neurological Press, 1997:43-45.
5. Toyka KV, Heininger K. Humoral factors in peripheral nerve disease. Muscle Nerve 1987;10:222-232.
6. Van den Berg LH, Oey PL, Wokke JHJ, Veldman H, Wieneke GH, Notermans SHW. Features of the Guillain-Barré syndrome in mice following intraperitoneal injection of patients serum. J Neurol Sci 1994;127:103-106.
7. Buchwald B, Toyka KV, Zielasek J, Weishaupt A. Schweiger S, Dudel J. Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: a macro-patch-clamp study. Ann Neurol 1998;44:913-922.
8. Roberts M, Willison H, Vincent A, Newsom-Davis J. Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release. Lancet 1994;343:454-455.
9. Buchwald B, Weishaupt A, Toyka KV, Dudel J. Immunoglobulin G from patients with Miller-Fisher syndrome rapidly and reversibly depresses evoked quantal release at the neuromuscular junction of mice. Neurosci Lett 1995;201:163-166.
10. Buchwald B, Weishaupt A, Toyka KV, Dudel J. Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals. Eur J Neurosci 1998;10:281-290.
11. Wagner AL, Buchtal F. Motor and sensory conduction in infancy and childhood: a reappraisal. Dev Med Child Neurol 1972;14:189-216.
12. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27(suppl):S21-S24.
13. Enders U, Karch H, Toyka KV, et al. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders. Ann Neurol 1993;34:136-144.
14. Zielasek J, Ritter G, Magi S, Hartung HP, Toyka KV. A comparative trial of anti-glycoconjugate antibody assays: IgM antibodies to GM1. J Neurol 1994;241:475-480.
15. Besinger U, Toyka KV, Hömberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking against acetylcholine receptors with changes in disease severity. Neurology 1983; 33:1316-1321.
16. Wintzen AR, Plomp JJ, Molenaar PC, et al. Acquired slow-channel syndrome: a form of myasthenia gravis with prolonged open time of the acetylcholine receptor channel. Ann Neurol 1998;44:657-664.
17. Motomura M, Johnson I, Lang B, et al. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995;58:85-87.
18. Bretag AH. Synthetic interstitial fluid for isolated mammalian tissue. Life Sci 1969;8:319-329.
19. Dudel J. Calcium dependence of quantal release triggered by graded depolarization pulses to nerve terminals on crayfish and frog muscle. Pflugers Arch 1989;415:289-298.
20. Villarroel A, Sakmann B. Calcium permeability increase of endplate channels in rat during postnatal development. J Physiol (Lond) 1996;496:331-338.
21. Hartung HP, van der Meché, Pollard JD. Guillain-Barré syndrome, CIDP and other immune mediated neuropathies. Curr Opin Neurol 1998;11:497-513.
22. Marcus DM, Latov N, Hsi BP, Gillard BK, and participating laboratories. Measurement and significance of antibodies against GM1 ganglioside. J Neuroimmunol 1989;25:255-259.
23. Ogawa-Goto K, Abe T. Gangliosides and glycosphingolipids of peripheral nervous system myelins: a minireview. Neurochem Res 1998;23:305-310.
24. Smith RG, Hamilton S, Hofmann F, et al. Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis. N Engl J Med 1992;327:1721-1728.
25. Engel AG. The neuromuscular junction. In: Engel AG, Franzini-Armstrong C, eds. Myology. 2nd ed. McGraw Hill, 1994:291-293.
26. Hall ZW, Sanes JR. Synaptic structure and development: the neuromuscular junction. Cell 1993;72(suppl):99-121.
27. Sakmann B, Brenner HR. Change in synaptic channel gating during neuromuscular development. Nature 1978;276:401-402.
28. Mishina M, Takai T, Imoto K, et al. Molecular distinction between fetal and adult forms of muscle acetylcholine receptor. Nature 1986;321:406-411.
29. Witzemann V, Schwarz H, Koenen M, et al. Acetylcholine receptor ∈-subunit deletion causes muscle weakness and atrophy in juvenile and adult mice. Proc Natl Acad Sci USA 1996; 93:13286-13291.
30. Schuetze SM, Vincini S, Hall ZW. Myasthenic serum selectively blocks acetylcholine receptors with long channel open times at developing rat endplates. Proc Natl Acad Sci USA 1985;82:2533-2537.
31. Hall ZW, Gorin PD, Silberstein L, Bennett C. A postnatal change in the immunological properties of the acetylcholine receptor at rat muscle endplates. J Neurosci 1985;5:730-734.
32. Breugelmans JG, Bazzy AR. Developmental differences in endplate response to P-type calcium channel blockade in the rat diaphragm. Brain Res Dev Brain Res 1997;101:227-281.
33. 2+ channels coupled to acetylcholine release. Neuron 1992;8:715-724.
34. White MG, Crumling MA, Meriney SD. Developmental changes in calcium current pharmacology and somatostatin inhibition in chick parasympathetic neurons. J Neurosci 1997; 17:6302-6313.
35. Riemersma S, Vincent A, Beeson D, et al. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J Clin Invest 1996;98:2358-2363.
36. Vernet-der Garabedian B, Lakovy M, Eymard B, et al. Association of neonatal myasthenia gravis with antibodies against the fetal acetylcholine receptor. J Clin Invest 1994;4:555-559.
37. Gardnerova M, Eymard B, Morel E, et al. The fetal/adult acetylcholine receptor antibody ratio in mothers with myasthenia gravis as a marker for transfer of the disease to the newborn. Neurology 1997;48:50-54.
38. Hesselmans LFGM, Jennekens FGI, van den Oord CJM, Veldman H, Vincent A. Development of innervation of skeletal muscle fibers in man: relation to acetylcholine receptors. Anat Rec 1993;236:553-562.
39. Darras BT. Neuromuscular disorders in the newborn. Clin Perinatol 1997;24:827-844.
40. Cornblath DR, Sladky JT, Sumner AJ. Clinical electrophysiology of infantile botulism. Muscle Nerve 1983;6:448-452.
41. Cornblath DR. Disorders of neuromuscular transmission in infants and children. Muscle Nerve 1986;9:606-611.